SELLAS Life Sciences (SLS) Accounts Payables (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Accounts Payables data on file, last reported at $3.6 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $3.6 million, down 3.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 million (down 3.27% YoY), and the FY2025 annual result was $2.9 million, down 15.77% from the prior year.
• Accounts Payables rose to $3.6 million in Q1 2026 per SLS's latest filing, from $2.9 million in the prior quarter.
• Over five years, Accounts Payables peaked at $7.4 million in Q1 2024 and troughed at $2.1 million in Q3 2022.
• A 5-year average of $3.9 million and a median of $3.5 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables surged 139.01% in 2024, then plunged 49.31% in 2025.
• A 5-year view of Accounts Payables shows it stood at $3.4 million in 2022, then soared by 67.98% to $5.6 million in 2023, then sank by 37.93% to $3.5 million in 2024, then declined by 15.77% to $2.9 million in 2025, then grew by 23.24% to $3.6 million in 2026.
• Business Quant data shows SLS's Accounts Payables at $3.6 million in Q1 2026, $2.9 million in Q4 2025, and $2.3 million in Q3 2025.